Centre Francois Baclesse — Clinical Trial Site

283 Registered trials

143 Currently recruiting

Organisation

Centre Francois Baclesse

Location

Caen Cedex 5, France

Identifier

ORG-100008458

Address

3 Avenue Du General Harris, Cs 45026, 14076, France

Departments

-
03309: Oncologie Medicale - Service de pathologie mammaire
1305: Service d'Oncologie médicale
2102; Oncology
2305: Pneumologie
2313: Department of pneumology
2317 Oncology Medical
Breast Oncology
breast pathology
Breast pathology department
Calvados
Cancérologie et Médecine d'organes
Centre François Baclesse
Chirurgie
Chirurgie gynécologique
Clinical Research Department
Clinical research unit
Comité digestif
Comité Sein et Radiothérapie
Comité Uro- Gynécologie
Comité Uro-Gynécologie
Département d'Oncologie Médicale
Département de cancérologie gynécologique
Département de dermatologie
Département de Médecine Oncologique
Departement of Breast pathology
Départements de gynécologie et d'urologie
Department of Gynecology and Urology
Department of Pneumology
Digestive Oncology
Digestive oncology department
Digestive Pathology
Digestive surgery
Douleur
Gastroenterology
General Medicine
Gynecological pathologies
Gynécologie
Gynécologie et urologie
Gynecology and Urology
Hepato-Gastro-Entérology
Hepato-gastroenterology
Internal Medicine
Maladies digestives
médecine nucléaire
medecine nuclear department
Medical Oncology
Medical Oncology Department
Medical Oncology-Cancerology Department
N/A
NA
Nuclear Medicine and Thyroid Unit
Onco-dermatologue
oncol
Oncolgie
oncolgie medicale
Oncolgoie
ONCOLOGIE
Oncologie Digestive
Oncologie Médicale
Oncologie Médicale - Cancérologie
Oncologie médicale - essais précoces
Oncologie Médicale-Cancérologie
ONCOLOGIE OPTION MEDICALE
Oncologue
Oncology
Oncology Department
Oncology for pediatrics
Oncology medical
Oncology Unit
Oncology-Neurology
Oncology-Radiotherapy
Pathologie Digestive
Pathologie mammaire
[email protected]
Pneumologie
Pneumology
Pneumonology
Radiation oncology
Radiothérapie
Radiotherapy
Radiotherapy department
Radiotherapy for pediatrics
Radiotherapy Oncology
Respiratory Diseases and Thoracic Oncology
Sarcoma department
service d'oncologie
Service d'Oncologie Médicale
Service de Gynecologie et du Sein
Service de pathologie mammaire
Service de Pneumologie
Service de Radiotherapie et Oncologie Medicale
Service de recherche clinique
Service Oncologie
Service oncologie médicale
Surgery
UCP Digestif
Unité d'investigation clinique
Unite d’investigation, de recherche, d’innovation et de soins (IRIS)
Unité de Recherche Clinique
Unité IRIS (Investigation, Recherche, Innovation et Soins)
Urologie-Gynécologie
Urology & Clinic Research
Urology and Clinical Research

Clinical trials at this site (283)

Search interface

Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers Recruiting

2023-509767-25-00 Advanced PRAME Positive Cancers 1 2024-11-07
Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg… Recruiting

2023-504620-26-00 Triple negative breast cancer 4 2024-11-04
A prospective, multicentre, open-label, randomized, Phase II study of Pembrolizumab in combination with neo-adjuvant EC-Paclitaxel regimen i… Recruiting

2024-514899-41-00 Breast cancer 4 2024-10-31
An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch… Recruiting

2024-516782-36-00 metastatic or recurrent endometrial or ovarian carcinos 4 2024-10-15
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-507482-26-00 Castrate-resistant prostate cancer with oligometastases 5 2024-10-04
OPEN-LABEL PHASE II EFFICACY STUDY OF REPOTRECTINIB IN FRAIL (PS ≥2) AND /OR ELDERLYPATIENTS WITH ROS1-REARRANGED ADVANCED NSCLC Recruiting

2023-509073-23-00 Stage III/IV non-small-cell lung cancer (NSCLC) harbori 4 2024-10-01
HARMONi-3 Recruiting

2024-513087-26-00 Metastatic Non-small Cell Lung Cancer 5 2024-09-10
Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard… Recruiting

2022-502408-57-00 Novo metastatic hormone-sensitive prostate cancer (mHSP 5 2024-09-04
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa… Recruiting

2023-508260-30-01 Patients with poor prognostic OVARian cancers based on 5 2024-07-30
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu… Recruiting

2024-515788-73-00 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCE 4 2024-07-30
Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI Recruiting

2023-505298-34-00 Patients with dMMR/MSI (non-colorectal/non-endometrial) 4 2024-07-18
Study of RMC-6291 and RMC-6236 With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A Recruiting

2023-509571-16-00 Lung Cancer 3 2024-07-17
A study of RMC-6236 in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B Recruiting

2023-509572-42-00 Lung Cancer 3 2024-07-17
Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting

2023-504962-52-00 Triple negative breast cancer. 5 2024-07-10
Personalized medicine for advanced biliary cancer patients Recruiting

2023-508100-38-00 Advanced Biliary Cancer (ABC) 5 2024-06-24
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Can… Recruiting

2023-507914-28-00 Platinum-resistant, high-grade serous ovarian cancer (O 10 2024-06-19
FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and … Recruiting

2023-506590-35-00 Large-Cell NeuroEndocrine Carcinoma of the lung 4 2024-06-13
A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un… Recruiting

2023-508613-17-00 Neoplasms, Head and Neck 5 2024-05-29
EstroTEP and circulating biomarkers for ER-positive HER2-negative metastatic breast cancer patients Recruiting

2023-506282-66-00 Women with ER+ HER2- metastatic breast cancer who progr 5 2024-05-27
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CD… Recruiting

2023-506888-34-00 Advanced or metastatic solid tumors including hormone r 1 2024-05-22
Gut microbiome intervention with EXL01 in combination with nivolumab and FOLFOX as first-line treatment for patients with PD-L1 CPS ≥5 metas… Recruiting

2023-506753-38-00 metastatic gastric adenocarcinoma 4 2024-04-16
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting

2023-503317-29-00 Metastatic renal cell carcinoma (mRCC) 5 2024-04-12
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08